Research programme: anti-cancer monolconal antibodies - Abeome CorporationAlternative Names: Anti-OX-40; Anti-PD-L1; Anti-T-cell agonists
Latest Information Update: 13 Sep 2016
At a glance
- Originator Abeome Corporation
- Class Monoclonal antibodies
- Mechanism of Action OX40 ligand inhibitors; Programmed cell death 1 ligand 2 protein inhibitors; T cell activation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 09 Sep 2016 Early research in Cancer in USA (Parenteral) before September 2016 (Abeome's pipeline, September 2016)